Ambispective Cohort Study of Precision Medicine for Primary Hepatobiliary Cancer Based on Next-generation Sequencing

Exclusion Criteria

• •1. Hepatobiliary cancer patient with stageI-III, or with any of the following items will not be eligible for screening. Such as, suitable for the treatment of radical resection, radical resection but evaluation unmeasurable.
• •2. The result of NGS test show the patient has no gene mutation, or has gene mutation but no medicine.
• •3. ECOG performance status ≥ 3.
• •4. Female patients who are pregnant or not using a contraceptive method of birth control.
• •5. History or presence of serious cardiovascular or cerebrovascular abnormalities.
• •6. Abnormalities of the hepatic or renal functions, such as jaundice, ascites, bilirubin ≥ 1.5×ULN, alkaline phosphatase ≥ 3×ULN, persistent protein urine≥ grade 3 (according to National Cancer Institute \[NCI\] Common Terminology Criteria for Adverse Events \[CTC-AE\] v4.0), creatinine ratio \> 3.5g/24 hours, renal failure.
• •7. Persistent infection \> grade 2 (according to National Cancer Institute \[NCI\] Common Terminology Criteria for Adverse Events \[CTC-AE\] v4.0).
• •8. Patient has underwent a major operation 4 weeks prior to screening or has not yet recovered from the operation.
• •9. Patient with epilepsy, known or untreated brain metastases.
• •10. The presence of wounds, ulcers or fractures that can not be healed, or with a past history of transplantation.
• •11. The presence of bleeding events ≥grade 3 (according to National Cancer Institute \[NCI\] Common Terminology Criteria for Adverse Events \[CTC-AE\] v4.0) , present evidence or past history of coagulation dysfunction disorders.
• •12. Known human immunodeficiency virus (HIV) infection history.
• •13. Patient with drug abuse or unstable compliance.
• •14. The presence of unresolved toxicity caused by any previous treatment/operation \> grade 1 (according to National Cancer Institute \[NCI\] Common Terminology Criteria for Adverse Events \[CTC-AE\] v4.0), except alopecia, anemia or hypothyroidism).
• •15. Investigator consider that the patient should not be enrolled in this study by careful assessment.
• •16. The subjects participate in any other clinical trial in the meantime.